LungLifeAI Logo

Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Description of the Business

Names of the directors, biographical details and responsibilities

Corporate governance

Country of incorporation / operation

Shareholder Information

  • Other Exchanges and Trading Platforms
  • Shares in Issue
  • Significant Shareholdings
  • Director Shareholdings
  • Shares Not in Public Hands
  • Restrictions in Transfer of AIM Securities
  • UK City Code on Takeovers and Mergers

Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

December 23, 2019

LungLife AI Receives CLIA certification for its Cancer Diagnostic Laboratory

LungLife AI the developer of an Artificial Intelligence (AI) enabled non-invasive liquid biopsy test for the early detection of lung cancer, announced today that the Company has received certification from the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the US Department of Health and Human Services (HHS) Center for […]
• Read More
1 35 36 37
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down